1
|
Venkatakrishnan K, Burgess C, Gupta N, Suri A, Takubo T, Zhou X, DeMuria D, Lehnert M, Takeyama K, Singhvi S, Milton A. Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles. Clin Transl Sci 2016; 9:9-22. [PMID: 26836226 PMCID: PMC5351319 DOI: 10.1111/cts.12386] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Revised: 12/22/2015] [Accepted: 01/05/2016] [Indexed: 12/13/2022] Open
Affiliation(s)
- K Venkatakrishnan
- Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA
| | - C Burgess
- Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA
| | - N Gupta
- Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA
| | - A Suri
- Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA
| | - T Takubo
- Takeda Pharmaceutical Company Limited, Tokyo, Japan
| | - X Zhou
- Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA
| | - D DeMuria
- Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA
| | - M Lehnert
- Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA
| | - K Takeyama
- Takeda Pharmaceutical Company Limited, Tokyo, Japan
| | - S Singhvi
- Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA
| | - A Milton
- Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts, USA
| |
Collapse
|
2
|
Nomura N, Saito K, Ikeda M, Yuasa S, Pastore M, Chabert C, Kono E, Sakai A, Tanaka H, Ikemoto T, Takubo T. Evaluation of the Microsemi CRP, an automated hematology analyzer for rapid 3-part WBC differential and CRP using whole blood. Int J Lab Hematol 2014; 37:466-73. [DOI: 10.1111/ijlh.12312] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Accepted: 10/01/2014] [Indexed: 10/24/2022]
Affiliation(s)
- N. Nomura
- HORIBA Medical; MiyanohigashiKisshoin; Minami-ku Kyoto Japan
| | - K. Saito
- HORIBA Ltd; Tokyo Office: Kanda-Awaji cho; Kanda Chiyoda-ku Tokyo Japan
| | - M. Ikeda
- HORIBA Medical; MiyanohigashiKisshoin; Minami-ku Kyoto Japan
| | - S. Yuasa
- HORIBA Medical; MiyanohigashiKisshoin; Minami-ku Kyoto Japan
| | - M. Pastore
- HORIBA ABX; Parc Euromédecine; Montpellier Cedex 4 France
| | - C. Chabert
- HORIBA ABX; Parc Euromédecine; Montpellier Cedex 4 France
| | - E. Kono
- Department of Central Laboratory; Osaka Medical College Hospital; Daigaku-machi Takatsuki Japan
| | - A. Sakai
- Department of Central Laboratory; Osaka Medical College Hospital; Daigaku-machi Takatsuki Japan
| | - H. Tanaka
- Department of Central Laboratory; Osaka Medical College Hospital; Daigaku-machi Takatsuki Japan
| | - T. Ikemoto
- Department of Central Laboratory; Osaka Medical College Hospital; Daigaku-machi Takatsuki Japan
| | - T. Takubo
- Department of Central Laboratory; Osaka Medical College Hospital; Daigaku-machi Takatsuki Japan
| |
Collapse
|
3
|
Tanada H, Ikemoto T, Masutani R, Tanaka H, Takubo T. Evaluation of the automated hematology analyzer ADVIA® 120 for cerebrospinal fluid analysis and usage of unique hemolysis reagent. Int J Lab Hematol 2013; 36:83-91. [PMID: 23937551 DOI: 10.1111/ijlh.12130] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2013] [Accepted: 06/12/2013] [Indexed: 11/30/2022]
Abstract
INTRODUCTION In this study, we evaluated the performance of the ADVIA 120 hematology system for cerebrospinal fluid (CSF) assay. METHODS Cell counts and leukocyte differentials in CSF were examined with the ADVIA 120 hematology system, while simultaneously confirming an effective hemolysis agent for automated CSF cell counts. RESULTS The detection limits of both white blood cell (WBC) counts and red blood cell (RBC) counts on the measurement of CSF cell counts by the ADVIA 120 hematology system were superior at 2 cells/μL (10(-6) L). The WBC count was linear up to 9.850 cells/μL, and the RBC count was linear up to approximately 20 000 cells/μL. The intrarun reproducibility indicated good precision. The leukocyte differential of CSF cells, performed by the ADVIA120 hematology system, showed good correlation with the microscopic procedure. The VersaLyse hemolysis solution efficiently lysed the samples without interfering with cell counts and leukocyte differential, even in a sample that included approximately 50 000/μL RBC. CONCLUSION These data show the ADVIA 120 hematology system correctly measured the WBC count and leukocyte differential in CSF. The VersaLyse hemolysis solution is considered to be optimal for hemolysis treatment of CSF when measuring cell counts and differentials by the ADVIA 120 hematology system.
Collapse
Affiliation(s)
- H Tanada
- Central Clinical Laboratory, Osaka Medical College Hospital, Osaka, Japan
| | - T Ikemoto
- Central Clinical Laboratory, Osaka Medical College Hospital, Osaka, Japan
| | - R Masutani
- Central Clinical Laboratory, Osaka Medical College Hospital, Osaka, Japan
| | - H Tanaka
- Central Clinical Laboratory, Osaka Medical College Hospital, Osaka, Japan
| | - T Takubo
- Department of Clinical and Laboratory Medicine, Osaka Medical College, Osaka, Japan
| |
Collapse
|
4
|
Doi T, Takiuchi H, Ohtsu A, Fuse N, Goto M, Yoshida M, Dote N, Kuze Y, Jinno F, Fujimoto M, Takubo T, Nakayama N, Tsutsumi R. Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. Br J Cancer 2012; 106:666-72. [PMID: 22240796 PMCID: PMC3322948 DOI: 10.1038/bjc.2011.590] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND This phase I first-in-human study was conducted in Japanese patients to investigate the safety, pharmacokinetics (PKs), and determine the maximum tolerated dose (MTD) of oral TAK-285, a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. METHODS The TAK-285 dose was escalated until MTD was determined. A second patient cohort received TAK-285 at the MTD for at least 4 weeks. RESULTS In all, 26 patients received TAK-285 at doses ranging from 50 to 400 mg once daily (q.d.) or twice daily (b.i.d.); 20 patients made up the dose escalation cohort and the remaining 6 patients were the repeated administration cohort. TAK-285 was well tolerated. Dose-limiting toxicities noted in two patients who received 400 mg b.i.d. were grade 3 increases in aminotransferases and grade 3 decreased appetite. Consequently, the MTD was determined to be 300 mg b.i.d. Absorption of TAK-285 was rapid after oral dosing, and plasma exposure at steady-state increased in a dose-proportional fashion for doses ranging from 50 to 300 mg b.i.d. A partial response was observed for one patient with parotid cancer who received 300 mg b.i.d. CONCLUSION The toxicity profile and PK properties of oral TAK-285 warrant further evaluation.
Collapse
Affiliation(s)
- T Doi
- Division of Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ikeda M, Okusaka T, Fukutomi A, Otani S, Shibayama K, Takubo T, Gansert J. 6587 POSTER A Phase 1b, Open-Label Study to Evaluate the Safety of Ganitumab (AMG 479) in Combination With Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71898-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
6
|
Doi T, Fuse N, Yoshino T, Murakami H, Yamamoto N, Boku N, Otani S, Shibayama K, Takubo T, Elwyn L. Phase I study of AMG 479, a fully human monoclonal antibody against the type 1 insulin-like growth factor receptor (IGF-1R), in Japanese patients (pts) with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.318] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
318 Background: AMG 479 is a fully human monoclonal antibody against human IGF-1R that inhibits the survival and proliferative signals driven by IGF-1 and -2. Methods: Patients (Pts) were enrolled into 1 of 3 dose cohorts (6, 12 or 20 mg/kg) of single-agent AMG 479 administered intravenously Q2W. Dose-limiting toxicity (DLT) was assessed for the first 28 days. The primary objectives were to assess the safety, tolerability, and pharmacokinetics (PK) of AMG 479 in Japanese pts with advanced solid tumors. An exploratory pharmacodynamic (PD) analysis was done to investigate the relationship between exposure and changes in the level of circulating factors in IGF-1R pathway (IGFBP-3 and total IGF-1). Results: Nineteen pts with ECOG 0-1 (6 in cohort 1 and 3, 7 in cohort 2) received at least 1 dose of AMG 479. Median age was 58.0 years. Tumor types included: breast (4), gastric (3), rectal (2), NSCL (2), thymic (2), and other cancers (6). Enrollment has been completed; 5 pts remained on study as of 15 March 2010. No DLTs were observed. Three serious adverse events (SAE) were reported, only respiratory tract haemorrhage in a subject with thymic carcinoma was considered by the investigator to be related to AMG 479. The most common grade ≥3 AEs were neutropenia (21%), leukopenia (16%) and lymphopenia (11%). There was a trend of dose-dependency on severity of thrombocytopenia, but not on that of neutropenia. No neutralizing anti-AMG 479 antibodies were detected. PK was dose-linear and similar to PK in non-Japanese pts. Tumor response data were available for 17 pts. Stable disease (defined as a lack of progression at the first 8-week assessment) as best response was reported in 6 pts and progressive disease was reported in 11 pts. Exploratory PD marker analysis demonstrating exposure dependent changes will be presented. Conclusions: AMG 479 up to 20 mg/kg was tolerable in Japanese pts with advanced solid tumors. The AE and PK profiles were similar to those previously observed in non-Japanese pts. An international phase 3 study in metastatic pancreatic cancer pts is planned based on the promising results from phase 1b/2 study (ASCO 2010, Abs 4035). [Table: see text]
Collapse
Affiliation(s)
- T. Doi
- National Cancer Center Hospital East, Kashiwa, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Takeda Bio Development Center, Tokyo, Japan; Amgen, Thousand Oaks, CA
| | - N. Fuse
- National Cancer Center Hospital East, Kashiwa, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Takeda Bio Development Center, Tokyo, Japan; Amgen, Thousand Oaks, CA
| | - T. Yoshino
- National Cancer Center Hospital East, Kashiwa, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Takeda Bio Development Center, Tokyo, Japan; Amgen, Thousand Oaks, CA
| | - H. Murakami
- National Cancer Center Hospital East, Kashiwa, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Takeda Bio Development Center, Tokyo, Japan; Amgen, Thousand Oaks, CA
| | - N. Yamamoto
- National Cancer Center Hospital East, Kashiwa, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Takeda Bio Development Center, Tokyo, Japan; Amgen, Thousand Oaks, CA
| | - N. Boku
- National Cancer Center Hospital East, Kashiwa, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Takeda Bio Development Center, Tokyo, Japan; Amgen, Thousand Oaks, CA
| | - S. Otani
- National Cancer Center Hospital East, Kashiwa, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Takeda Bio Development Center, Tokyo, Japan; Amgen, Thousand Oaks, CA
| | - K. Shibayama
- National Cancer Center Hospital East, Kashiwa, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Takeda Bio Development Center, Tokyo, Japan; Amgen, Thousand Oaks, CA
| | - T. Takubo
- National Cancer Center Hospital East, Kashiwa, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Takeda Bio Development Center, Tokyo, Japan; Amgen, Thousand Oaks, CA
| | - L. Elwyn
- National Cancer Center Hospital East, Kashiwa, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Takeda Bio Development Center, Tokyo, Japan; Amgen, Thousand Oaks, CA
| |
Collapse
|
7
|
Uvet H, Hasegawa A, Ohara K, Takubo T, Mae Y, Arai T. Vision-Based Automated Single-Cell Loading and Supply System. IEEE Trans Nanobioscience 2009; 8:332-40. [DOI: 10.1109/tnb.2009.2035280] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
8
|
Takubo T, Wakui S, Daigo K, Kurokata K, Ohashi T, Katayama K, Hino M. Expression of non-muscle type myosin heavy polypeptide 9 (MYH9) in mammalian cells. Eur J Histochem 2009. [DOI: 10.4081/845] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Myosin is a functional protein associated with cellular movement, cell division, muscle contraction and other functions. Members of the myosin super-family are distinguished from the myosin heavy chains that play crucial roles in cellular processes. Although there are many studies of myosin heavy chains in this family, there are fewer on non-muscle myosin heavy chains than of muscle myosin heavy chains. Myosin is classified as type I (myosin I) or type II (myosin II). Myosin I, called unconventional myosin or mini-myosin, has one head, while myosin II, called conventional myosin, has two heads. We transfected myosin heavy polypeptide 9 (MYH9) into HeLa cells as a fusion protein with enhanced green fluorescent protein (EGFP) and analyzed the localization and distribution of MYH9 in parallel with those of actin and tubulin. The results indicate that MYH9 colocalizes with actin stress fibers. Since it has recently been shown by genetic analysis that autosomal dominant giant platelet syndromes are MYH9-related disorders, our development of transfected EGFP-MYH9 might be useful for predicting the associations between the function of actin polymerization, the MYH9 motor domain, and these disorders.
Collapse
|
9
|
Kim IH, Tanaka H, Iwasaki T, Takubo T, Morioka T, Kato Y. Classification of the degradability of 30 pharmaceuticals in water with ozone, UV and H2O2. Water Sci Technol 2008; 57:195-200. [PMID: 18235171 DOI: 10.2166/wst.2008.808] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Experiments were conducted to assess the degradability of 30 PPCPs, selected on the basis of consumption and environmental relevance, by O3 process, UV process and AOPs consisting of UV/ H2O2, O3/UV and O3/H2O2. A batch reactor with volume of 22L of water including the PPCPs was used. For UV process, combination of UV and H2O2 or O3 that can generate OH radicals was capable of degrading the PPCPs faster than UV radiation alone. On the other hand, O3 process and O3-based/UV-based AOPs could remove a variety of the PPCPs effectively, while some PPCPs such as 2-QCA, DEET and cyclophosphamide showed a relatively low degradability compared with the other PPCPs. However, further evaluation on formation of intermediate products resulting from the degradation of the parent PPCPs will be needed because DOC concentration was not decreased with lowered concentrations of the PPCPs.
Collapse
Affiliation(s)
- I H Kim
- Research Center for Environmental Quality Management, Kyoto University, 1-2 Yumihama, Otsu, Shiga, 520-0811, Japan.
| | | | | | | | | | | |
Collapse
|
10
|
Yasumori T, Narita H, Matsuda T, Takubo T, Ogawa M, Ishii M, Hara K, Ishii Y, Okuyama K, Fujimoto G, Ochiai H, Kano A, Hasegawa S, Sato K, Taniguchi T. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese. Eur J Clin Pharmacol 2006; 62:939-46. [PMID: 16953457 DOI: 10.1007/s00228-006-0189-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2006] [Accepted: 07/24/2006] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To examine the inhibitory effect of finasteride 1 mg on the metabolism of omeprazole in genetically determined extensive (EMs) and poor metabolizers (PMs) for CYP2C19 in young healthy Japanese male subjects. METHODS Twenty-four volunteers participated in this study, among whom 12 were homozygous EMs and 12 were PMs for CYP2C19. A single center, controlled, randomized, open, crossover study with a 5 day washout between the two study periods was performed. Each of the six EMs and PMs received a single oral 20 mg dose of omeprazole on day 1 (treatment I). After a 5 day washout period, these subjects received 1 mg of finasteride once a day for three consecutive days, and a single oral 20 mg dose of omeprazole was co-administered on day 3 (treatment II). The 12 other EMs and PMs received treatments I and II in reverse. Plasma samples were collected for up to a 12 hours postdose of omeprazole, and the pharmacokinetic parameters of omeprazole were determined. RESULTS The geometric mean ratio (GMR) for the AUC((0-12 hr)) of omeprazole when co-administered with finasteride/omeprazole alone is 1.13 (90%CI, 1.03, 1.25) and 0.96 (0.88, 1.05) in EMs and PMs, respectively. Finasteride did not significantly alter C(max), T(max) and t(1/2) in both genotypes. CONCLUSION Finasteride 1 mg, widely used for the treatment of androgenetic alopecia in men, did not meaningfully increase omeprazole exposure (20 mg) in both EMs and PMs for CYP2C19. These results indicate that finasteride does not meaningfully inhibit CYP2C19 activity in vivo at the dose of 1 mg.
Collapse
Affiliation(s)
- T Yasumori
- Clinical Development Institute, Banyu Pharmaceutical Co. Ltd., Kitanomaru Square, 1-13-12, Kudan-Kita, Chiyoda-ku, Tokyo, 102-8667, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Takubo T, Kanashima H, Terada Y, Shibata H, Aoyama Y, Nakamae H, Yamamura R, Shima E, Makita K, Tanaka K, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N, Ohshima K. E-cadherin expression in lymph nodes of three patients with non-Hodgkin's lymphoma. ACTA ACUST UNITED AC 2003; 32:67-72. [PMID: 12243557 DOI: 10.1163/156855902760262781] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The E-cadherins are a family of cell-cell adhesion molecules. These molecules exhibit Ca2+ dependent cell adhesion and are expressed on epithelial cells. E-cadherin levels in serum are known to be significantly elevated in patients with epithelial carcinomas. We determined serum E-cadherin levels in 30 patients with non-Hodgkin's lymphoma (NHL) using an enzyme immunoassay and then investigated whether E-cadherin is expressed on lymphoma cells in lymph nodes of three cases selected to analyze from 15 cases of serum E-cadherin levels over mean + 2SD with monoclonal antibody immunohistochemistry. Results indicated that E-cadherin antigen is expressed on the lymphoma cells in these three patients with NHL, and that soluble E-cadherin might be released into blood from lymphoma cells. Expression of E-cadherin may contribute to the morphological appearance of some malignant lymphoma, although no conclusion can be drawn based on such small number of patients analyzed.
Collapse
Affiliation(s)
- T Takubo
- Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Takubo T, Kumura T, Nakamae H, Aoyama Y, Koh KR, Ohta K, Yamane T, Hino M, Kanashima H, Kamitani T, Ohta T, Kuwajima S, Tatsumi N. Urinary trypsin inhibitor levels in the urine of patients with haematological malignancies. Haematologia (Budap) 2003; 31:267-72. [PMID: 11855791 DOI: 10.1163/15685590152763836] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The urinary trypsin inhibitor (UTI) levels in the urine of patients with various haematological malignancies were determined, using automated latex agglutination immunoturbidimetry. The mean UTI levels in urine in acute non-lymphocytic leukaemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, and multiple myeloma groups were significantly elevated, compared with the normal control group. It was found that the UTI level in urine changed from an elevated value to a normal value with haematological improvement by chemotherapy in a patient with myelodysplastic syndrome included in a previous study. These results suggest tha
Collapse
Affiliation(s)
- T Takubo
- Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Takubo T, Kumura T, Kanashima H, Nakao T, Nakamae H, Aoyama Y, Yamamura R, Ohta T, Koh KR, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Analysis of IL-18 bioactivity and IL-18 mRNA in three patients with adult T-cell leukaemia, acute mixed lineage leukaemia, and acute lymphocytic leukaemia accompanied with high serum IL-18 levels. Haematologia (Budap) 2003; 31:231-5. [PMID: 11855785 DOI: 10.1163/15685590152763773] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Interleukin-18 (IL-18) bioactivity in sera and IL-18 mRNA expression in leukaemia cells of three patients with adult T-cell leukaemia (ATL), acute mixed lineage leukaemia (AMLL) and acute lymphocytic leukaemia (ALL) accompanied with high serum IL-18 levels have been analysed. There was little serum IL-18 bioactivity in the three patients with ATL, AMLL and ALL, while IL-18 mRNA expression was detected in leukaemia cells of all three patients.
Collapse
Affiliation(s)
- T Takubo
- Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Aoyama Y, Yamamura R, Shima E, Nakamae H, Makita K, Kho G, Ohta K, Yamane T, Takubo T, Hino M. Successful treatment with reduced-intensity stem cell transplantation in a case of relapsed refractory central nervous system lymphoma. Ann Hematol 2003; 82:371-3. [PMID: 12719887 DOI: 10.1007/s00277-003-0651-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2002] [Accepted: 03/28/2003] [Indexed: 10/26/2022]
Abstract
A 33-year-old male with refractory relapsed central nervous system lymphoma underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-identical sibling after reduced-intensity conditioning chemotherapy. The preparative regimen for allo-HSCT consisted of fludarabine and busulfan. Cyclosporine (CsA) and short-term methotrexate were used as prophylaxis for acute graft-versus-host disease (GVHD). Although CsA was quickly reduced to induce a graft-versus-lymphoma (GVL) effect, no symptoms of GVHD and GVL effect were evident. Donor lymphocyte infusion (DLI) was performed on day +40 following transplantation. The patient developed acute GVHD (grade III) after DLI, and lymphoma regression was observed after the occurrence of GVHD. Four months after transplantation, complete remission was achieved with extensive chronic GVHD, and the patient continues to be disease free at 15 months after transplantation.
Collapse
Affiliation(s)
- Y Aoyama
- Department of Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, 1-4-3 Asahimachi, Abeno-ku, 545-8586, Osaka-shi, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Hino M, Yamane T, Park K, Takubo T, Ohta K, Kitagawa S, Higuchi K, Arakawa T. Platelet recovery after eradication of Helicobacter pylori in patients with idiopathic thrombocytopenic purpura. Ann Hematol 2003; 82:30-2. [PMID: 12574961 DOI: 10.1007/s00277-002-0579-8] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2002] [Accepted: 10/23/2002] [Indexed: 12/24/2022]
Abstract
The association between Helicobacter pylori ( H. pylori) infection and idiopathic thrombocytopenic purpura (ITP) has been reported by several groups. We investigated the prevalence of H. pylori infection and the effectiveness of its eradication in Japanese patients with ITP. H. pylori infection was found in 21 of 30 patients (70.0%) by (13)C urea breath test and presence of serum antibodies to H. pylori. H. pylori was eradicated in 18 of the 21 infected patients (85.7%) by administration of a proton pump inhibitor and two kinds of antibiotics. In only one patient was medication discontinued due to skin rash on the 4th day of treatment. Platelet recovery was obtained in ten patients (55.6%). In two patients with treatment failure, platelet recovery was obtained after successful re-eradication. In three patients without H. pylori infection, platelet counts did not significantly increase with the same treatment. On the other hand, eradication therapy did not affect platelet counts in patients with gastric ulcer. In conclusion, H. pylori eradication can be used for initial treatment with tolerable adverse effects in some ITP patients.
Collapse
Affiliation(s)
- M Hino
- Department of Clinical Hematology and Clinical Diagnostics, Osaka City University, Graduate School of Medicine, 1-4-3, Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
The feasibility of CTAD (a mixture of citrate, theophylline, adenosine and dipyridamole) as a new anticoagulant for medical laboratory use was studied prospectively. Whole blood anticoagulated with CTAD exhibited results very similar to those of blood anticoagulated with EDTA on complete blood count and automated white cell differential except for a slight decrease in platelet count and mean platelet volume. Chemistry test data for plasma obtained from CTAD whole blood were close to those obtained for matched sera. Among coagulation tests, prothrombin time, activated partial thromboplastin time and fibrinogen concentrations were close to those obtained with citrate plasma. Based on the results, CTAD was judged to be a good candidate as a new anticoagulant.
Collapse
Affiliation(s)
- M. Yokota
- Department of Clinical and Laboratory MedicineOsaka City University Medical School1-4-3 AshinachiAbenoOsaka545-8585Japan
| | - N. Tatsumi
- Department of Clinical and Laboratory MedicineOsaka City University Medical School1-4-3 AshinachiAbenoOsaka545-8585Japan
- Noriyuki TatsumiInternational Buddhist University3-2-1 GakuenmaeHabikinoOsaka583-8501Japan
| | - I. Tsuda
- Department of Clinical and Laboratory MedicineOsaka City University Medical School1-4-3 AshinachiAbenoOsaka545-8585Japan
| | - T. Nishioka
- Department of Clinical and Laboratory MedicineOsaka City University Medical School1-4-3 AshinachiAbenoOsaka545-8585Japan
| | - T. Takubo
- Department of Clinical and Laboratory MedicineOsaka City University Medical School1-4-3 AshinachiAbenoOsaka545-8585Japan
| |
Collapse
|
17
|
Takubo T, Wakui S, Daigo K, Kurokata K, Ohashi T, Katayama K, Hino M. Expression of non-muscle type myosin heavy polypeptide 9 (MYH9) in mammalian cells. Eur J Histochem 2003; 47:345-52. [PMID: 14706930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023] Open
Abstract
Myosin is a functional protein associated with cellular movement, cell division, muscle contraction and other functions. Members of the myosin super-family are distinguished from the myosin heavy chains that play crucial roles in cellular processes. Although there are many studies of myosin heavy chains in this family, there are fewer on non-muscle myosin heavy chains than of muscle myosin heavy chains. Myosin is classified as type I (myosin I) or type II (myosin II). Myosin I, called unconventional myosin or mini-myosin, has one head, while myosin II, called conventional myosin, has two heads. We transfected myosin heavy polypeptide 9 (MYH9) into HeLa cells as a fusion protein with enhanced green fluorescent protein (EGFP) and analyzed the localization and distribution of MYH9 in parallel with those of actin and tubulin. The results indicate that MYH9 colocalizes with actin stress fibers. Since it has recently been shown by genetic analysis that autosomal dominant giant platelet syndromes are MYH9-related disorders, our development of transfected EGFP-MYH9 might be useful for predicting the associations between the function of actin polymerization, the MYH9 motor domain, and these disorders.
Collapse
Affiliation(s)
- T Takubo
- Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, 1-4-3, Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
| | | | | | | | | | | | | |
Collapse
|
18
|
Takubo T, Kanashima H, Terada Y, Aoyama Y, Nakamae H, Yamamura R, Shima E, Makita K, Tanaka K, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Clinical significance of serum E-cadherin levels in patients with haematological malignancies. Haematologia (Budap) 2002; 31:319-25. [PMID: 12038515 DOI: 10.1163/15685590160141341] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
E-cadherin is a transmembrane glycoprotein that mediates Ca2+-dependent intracellular adhesion in normal epithelial cells. E-cadherin levels in serum are known to be significantly elevated in patients with epithelial carcinomas. However, the role of E-cadherin in haematopoietic cells is less clear. In this study, serum E-cadherin levels were therefore determined in patients with acute or chronic leukaemia, malignant lymphoma or myelodysplastic syndromes. Significant elevation of serum E-cadherin levels was detected in patients with haematological malignancies, and between types of acute leukaemias or subtypes of myelodysplastic syndromes, stages of malignant lymphoma, and phases of chronic leukaemia, respectively, compared with those in healthy adult volunteers. These findings suggest that E-cadherin might be expressed in malignant haematopoietic cells and might be useful as a diagnostic indicator in haematological malignancies.
Collapse
Affiliation(s)
- T Takubo
- Clinical Hematology and Clinical Diagnostics, Graduate School of Medicne, Osaka City University, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Takubo T, Fujino H, Hino M, Yamane T, Ohta K, Koh KR, Kumura T, Hashimoto S, Nakao T, Nakamae H, Aoyama Y, Nishiki S, Kinoshita Y, Kamitani T, Tatsumi N, Hojo S, Fujita J. Expression of KL-6 antigen on leukemia cells of a patient with chronic myelocytic leukemia in blastic phase. Haematologia (Budap) 2002; 31:173-6. [PMID: 11583030 DOI: 10.1163/15685590152492990] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
MESH Headings
- Antigens/blood
- Antigens/genetics
- Antigens, Neoplasm
- Biomarkers, Tumor/blood
- Blast Crisis/diagnosis
- Blast Crisis/immunology
- Blast Crisis/pathology
- Bone Marrow Cells/immunology
- Bone Marrow Cells/metabolism
- Bone Marrow Cells/pathology
- Glycoproteins/blood
- Glycoproteins/genetics
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Monocytes/immunology
- Monocytes/metabolism
- Monocytes/pathology
- Mucin-1
- Mucins
- RNA, Messenger/blood
- RNA, Neoplasm/blood
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Takubo T, Kumura T, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Elevation of serum procalcitonin level in a patient with chronic myelocytic leukemia. Haematologia (Budap) 2002; 31:177-9. [PMID: 11583031 DOI: 10.1163/15685590152493007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
21
|
Nishiki S, Hino M, Kumura T, Hashimoto S, Ohta K, Yamane T, Takubo T, Tatsumi N, Kitagawa S, Kamitani T, Watanabe Y, Shimada E, Juji T, Iida S. Effectiveness of washed platelet concentrate and red cell transfusions for a patient with anhaptoglobinemia with antihaptoglobin antibody. Transfus Med 2002; 12:71-3. [PMID: 11967140 DOI: 10.1046/j.1365-3148.2002.00350.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A 71-year-old Japanese male with myelodysplastic syndrome progressing to overt leukaemia and hepatocellular carcinoma developed dyspnea and urticaria immediately after infusion of platelet concentrate (PC). He exhibited an identical reaction following blood transfusion. Serum haptoglobin was undetectable. The patient was determined to be homozygous for Hp(del) by polymerase chain reaction (PCR). Antibody to haptoglobin was detected by enzyme-linked immunosorbent assay (ELISA) and Western blot analysis. No antibodies against human leucocyte antigen (HLA) or platelet-specific antigens were detected. Washed PC and washed red blood cells were effective in preventing the transfusion-related anaphylactoid reactions.
Collapse
Affiliation(s)
- S Nishiki
- Department of Clinical Hematology and Diagnostics, Osaka City University, Graduate School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Takubo T, Shibata H, Terada Y, Aoyama Y, Nakamae H, Yamamura R, Shima E, Makita K, Tanaka K, Ohta K, Yamane T, Hino M, Hashimoto S, Kamitani T, Tatsumi N. Serum sialyl Lewis(x) levels in patients with various haematologic malignancies. Haematologia (Budap) 2002; 32:147-9. [PMID: 12412734 DOI: 10.1163/156855902320387989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
Affiliation(s)
- T Takubo
- Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Shima E, Hino M, Yamane T, Aoyama Y, Nakamae H, Yamamura R, Makita K, Sugano Y, Yasuda S, Takubo T, Ohta K, Tatsumi N. Acute rhabdomyolysis following administration of high-dose cyclophosphamide: case report. Ann Hematol 2002; 81:55-6. [PMID: 11807638 DOI: 10.1007/s00277-001-0399-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2001] [Accepted: 10/11/2001] [Indexed: 11/28/2022]
Abstract
Rhabdomyolysis is an unusual complication of hematopoietic stem cell transplantation (HSCT). Cyclophosphamide has been one of the key drugs in the most common preparative regimen for HSCT. We present here a rare case of acute rhabdomyolysis following administration of high-dose cyclophosphamide. A 47-year-old woman with adult T-cell leukemia in remission was treated with high-dose cyclophosphamide as a preparative regimen for allogeneic bone marrow transplantation. Nineteen hours later, general convulsions and acidosis suddenly occurred. Levels of serum creatine kinase (skeletal muscle type), myoglobin, and aldolase were markedly elevated to 32870 IU/l, 640 ng/ml, and 240.3 IU/l, respectively. Rhabdomyolysis caused by high-dose cyclophosphamide was diagnosed, and the preparative chemotherapy was discontinued. Subsequently, her muscular signs and symptoms improved, and the results of laboratory examinations returned to normal after 2 weeks. She had previously been treated with conventional doses of cyclophosphamide, doxorubicin, vincristine, and prednisolone without evidence of rhabdomyolysis. Acute rhabdomyolysis may be an adverse effect specific to high-dose cyclophosphamide therapy.
Collapse
Affiliation(s)
- E Shima
- Department of Clinical Hematology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Fujino H, Ohta K, Taniue A, Nagao N, Hino M, Yamane T, Koh KR, Takeoka Y, Hirose A, Aoyama Y, Nakamae H, Terada Y, Takubo T, Tatsumi N. Primary refractoriness to platelet transfusion caused by Nak a
antibody alone. Vox Sang 2002. [DOI: 10.1046/j.0042-9007.2001.00140.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
25
|
Takubo T, Kanashima H, Terada Y, Shibata H, Aoyama Y, Nakamae H, Yamamura R, Shima E, Makita K, Tanaka K, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Clinical significance of serum E-selectin levels in patients with various haematologic malignancies. Haematol 2002; 32:97-100. [PMID: 12243563 DOI: 10.1163/156855902760262844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
26
|
Tanaka K, Migitani A, Teshima H, Tatsumi Y, Inoue T, Ohta K, Yamane T, Hino M, Takubo T, Tatsumi N. [Two cases of bronchus-associated lymphoid tissue lymphoma]. Rinsho Ketsueki 2001; 42:1170-5. [PMID: 11828719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
We report 2 cases of bronchus-associated lymphoid tissue lymphoma (BALT lymphoma), which is a rare disease. Patient 1 was a 76-year-old woman with a chief complaint of cough. Since plain chest radiography revealed an abnormal shadow in the hilum of the lung, she visited our hospital. Patient 2 was a 56-year-old man, who had been diagnosed as having pseudolymphoma at a medical check-up in a local hospital. During follow-up, however, he was referred to our hospital because of enlarged tumors and chest pain. In both patients, bronchofiberscopy demonstrated submucosal tumors and biopsy samples showed formation of lymphoepithelial lesions by centrocyte-like cells with a B-cell staining pattern. The patients were therefore diagnosed as having BALT lymphoma. Both received CEOP-E treatment, which improved the clinical symptoms but did not result in complete remission. The patients have been followed up after discontinuation of the medication. The progress of the disease has been slow, and both patients are alive as of September 2001.
Collapse
Affiliation(s)
- K Tanaka
- Department of Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Aoyama Y, Yamane T, Hino M, Ohta K, Nakamae H, Yamamura R, Koh KR, Takubo T, Inoue T, Tatsumi Y, Tatsumi N. Blastic NK-cell lymphoma/leukemia with T-cell receptor gamma rearrangement. Ann Hematol 2001; 80:752-4. [PMID: 11797118 DOI: 10.1007/s00277-001-0380-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2001] [Accepted: 08/22/2001] [Indexed: 10/27/2022]
Abstract
A 79-year-old Japanese man was admitted to our hospital with dyspnea in June 1999. Physical examination revealed general exanthema, hepatosplenomegaly, and lymphadenopathy. Increased numbers of abnormal cells were observed in peripheral blood; these cells were of lymphoblastic morphology with high nuclear/cytoplasm ratios and few azurophilic granules. Immunophenotypic analysis revealed positivity for CD2, CD4, CD56, and HLA-DR, and negativity for CD3, CD13, CD16, CD33, CD34, and T cell receptor (TCR). On genotypic analysis, TCRgamma chain was rearranged, but neither the TCRbeta chain nor TCRdelta chain. Despite an initial good response to chemotherapy the disease relapsed in the early stage, and the patient died 6 months after diagnosis.
Collapse
MESH Headings
- Aged
- Antigens, CD/analysis
- Biopsy
- Bone Marrow/pathology
- C-Reactive Protein/analysis
- Cell Nucleus/pathology
- Cytoplasm/pathology
- Erythema/pathology
- Fatal Outcome
- Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor
- HLA-DR Antigens/analysis
- Humans
- Immunophenotyping
- Killer Cells, Natural/immunology
- L-Lactate Dehydrogenase/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Lymphoid/diagnosis
- Leukemia, Lymphoid/genetics
- Leukemia, Lymphoid/pathology
- Male
- Receptors, Interleukin-2/analysis
- Skin/pathology
Collapse
Affiliation(s)
- Y Aoyama
- Department of Clinical Hematology, Osaka City University Medical School, 1-4-3, Asahimachi, Abeno-ku, Osaka-shi, Osaka, 545-8586 Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Tatsumi N, Tsuda I, Fukumori T, Hino M, Takubo T, Kondo H. A centrifuge-less plasma separation method from whole blood anticoagulated with EDTA-2K for the use of clinical laboratory tests. Osaka City Med J 2001; 47:177-88. [PMID: 11906128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
In the modern medical laboratory system, simple and rapid processing of specimens are required. In the current system with the transportation line, its centrifugation part would disturb smooth flow of the testing because it needs much time for the centrifugation. To solve the problems, a serum separation method was tried for the whole blood specimen using poly-L-lysine, concanavalin A and phyto-hemoagglutinin. Ploy-L-lysine with molecular weight 130,000 to 210,000 in a final concentration of 0.1% could accelerate blood sedimentation, although its supernatant contaminated platelets. Concanavalin and phytohemoagulutinin could accelerate the sedimentation and obtained plasma, but the method could yield enough amount of supernatant by 1 hour standing. As the purpose of this study is to develop a centrifugeless method, a sieve method using a steel mesh and a magnet was applied to the mixture of EDTA blood, red-cell adhesives and thrombin. The method was unique to separate plasma, but the yield was not so high and chemistry data were not fitted with serum data in some of tests. Thus, the trial would be a new technology, but it was judged that some further improvement will be needed technically.
Collapse
Affiliation(s)
- N Tatsumi
- Department of Clinical & Laboratory Medicine, Osaka City University Medical School, Osaka, Japan
| | | | | | | | | | | |
Collapse
|
29
|
Takubo T, Kumura T, Nakao T, Nakamae H, Aoyama Y, Kinoshita Y, Koh KR, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Expression of human interleukin-18 antigen in leukemia cells in a patient with acute mixed lineage leukemia. Haematologia (Budap) 2001; 31:69-71. [PMID: 11345407 DOI: 10.1163/15685590151092733] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Takubo T, Kumura T, Nakao T, Nakamae H, Aoyama Y, Nishiki S, Kinoshita Y, Koh KR, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Serum KL-6 levels in haematologic malignancies and their clinical application. Haematologia (Budap) 2001; 31:61-7. [PMID: 11345406 DOI: 10.1163/15685590151092724] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
A new reagent has been developed to determine D-arabinitol. This utilizes D-arabinitol 2-oxidoreductase derived from Bacillus sp. with high stability, and water-soluble tetrazolium salt, that can detect NADH with high sensitivity. Since this enzyme does not react to D-mannitol, elimination of D-mannitol is unnecessary. Thus, this is a much simpler process than currently available with commercial kits use D-arabinitol 4-oxidoreductase. The within-run and between-run precisions (CV) were 2.4-6.9% and 3.1-8.7%, respectively, whilst the correlation (r) between the results obtained with our proposed method (y) and those obtained with the commercial "Arabinitec-auto" kit (x) was 0.964 (y = 1.02x + 0.933 mumol/l; n = 69). However, some samples deviated remarkably from correlation in both methods. Our analyzing accuracy is satisfactory in clinical application, as it does not miss positive sample over cut-off value. We are refining this method by investigating why some specimens are apart from correlation significantly.
Collapse
Affiliation(s)
- M Hino
- Department of Clinical Hematology, Osaka City University Medical School, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
| | | | | | | | | | | |
Collapse
|
32
|
Hino M, Yamane T, Ohta K, Nakaie K, Kubota H, Fujino K, Takubo T, Tatsumi N. [Roles of clinical laboratory monitoring in bone marrow and peripheral blood stem cell transplantation]. Rinsho Byori 2001; 49:657-61. [PMID: 11519125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Hematopoietic stem cell transplantation(HSCT) increase the chances of cure of many hematological malignancy. The clinical laboratory plays a major role in support of HSCT. Both transplantation-specific laboratory test(tissue typing, assessment of graft viability/rejection, evaluation of minimal residual disease, and measurement of immunosuppressive drugs) and routine clinical laboratory tests(biochemical, hematological, serological, urinary, bacteriological, and physiological examinations) are significant. Hematopoietic stem cells(HSC) are usually assessed as CD34+ cells, while immature cells determined by automated hematology analyzers can simply evaluate HCS. These automated immature cell counts are earlier markers of engraftment following transplantation than the traditional indicators(neutrophils and platelets). After transplantation, infections, regimen-related toxicities, graft-versus host disease, veno-occlusive disease, and thrombotic microangiopathy are the serious complications, which are causes of expected mortality and morbidity in HSCT. Clinical laboratory monitoring may contribute early diagnosis and treatment of the complications, resulting in prevention of the adverse events.
Collapse
Affiliation(s)
- M Hino
- Clinical Hematology and Clinical Diagnostics, Osaka City University, Graduate School of Medicine, Osaka 545-8585
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Tsuji R, Tatsumi N, Hino M, Nishioka T, Takubo T. Tissue factor pathway inhibitor as a universal anticoagulant for use in clinical laboratory tests. TOHOKU J EXP MED 2001; 194:165-74. [PMID: 11693665 DOI: 10.1620/tjem.194.165] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Tissue factor pathway inhibitor (TFPI) is a protease inhibitor of extrinsic coagulation. The present study investigates the possibility of utilizing TFPI as a universal anticoagulant in clinical laboratory tests. The optimal concentration of TFPI for use in clinical laboratory tests was found to be 1 microl TFPI/ml blood (100 mmol TFPI/ml blood); the subsequent analyses were conducted at this concentration. In hematological tests, complete blood cell count and differential white blood cell count were done with an automatic blood analyzer. The results except for platelet and white blood cell counts were similar for ethylenediaminetetraacetic acid (EDTA)-treated and TFPI-treated samples. The effects of TFPI on platelet count were more pronounced when blood samples were stored at 4 degrees C than at room temperature. The effects of TFPI on cell morphology were evaluated by spreading blood samples into thin films and applying a Giemsa stain. The results showed that TFPI did not alter the morphology of blood cells. An automatic biochemical analyzer performed seventeen basic biochemical tests on serum samples and TFPI-treated plasma samples. The results of seventeen tests were comparable between TFPI-treated samples and EDTA-treated samples. The prothrombin time for TFPI-treated plasma samples was longer than that for citrated plasma samples. Nonetheless, in activated partial thromboplastin time tests, the addition of the reagent caused turbidity and partial coagulation, thus demonstrating that TFPI is not suitable for this assay. These findings suggest that although some tests cannot be performed with TFPI, this compound may be useful as a universal anticoagulant in the future.
Collapse
Affiliation(s)
- R Tsuji
- Department of Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Osaka, Japan
| | | | | | | | | |
Collapse
|
34
|
Fujino H, Ohta K, Taniue J, Nagao N, Hino M, Yamane T, Koh KR, Takeoka Y, Hirose A, Aoyama Y, Nakamae H, Terada Y, Takubo T, Tatsumi N, Taniue A. Primary refractoriness to platelet transfusion caused by Nak(a) antibody alone. Vox Sang 2001; 81:42-4. [PMID: 11520415 DOI: 10.1046/j.1423-0410.2001.00048.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND AND OBJECTIVES Anti-Nak(a), a platelet-specific antibody, occasionally causes platelet-transfusion refractoriness (PTR) together with human leucocyte antigen (HLA) antibodies. Anti-Nak(a) usually appears after frequent platelet transfusions or pregnancy. We report the first case of PTR caused by anti-Nak(a) alone. MATERIALS AND METHODS A 19-year-old male patient with testicular tumour showed PTR when receiving his first transfusion of platelets. Screening for platelet antigens and platelet antibodies revealed that he had type I CD36 (Nak(a)) deficiency and that anti-Nak(a), but not anti-HLA, was present before he received his first transfusion. RESULTS The transfusion of Nak(a)-negative, but HLA non-selected, platelets was effective in raising the platelet count. CONCLUSION Clinically significant Nak(a) antibody was present as naturally occurring antibody in a platelet glycoprotein IV (CD36)-negative non-transfused male patient.
Collapse
Affiliation(s)
- H Fujino
- Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Aoyama Y, Yamane T, Hino M, Ota K, Hasegawa T, Sakamoto C, Nakamae H, Yamamura R, Koh KR, Takubo T, Inoue T, Tsubaki K, Tatsumi N. Nodal gamma/delta T cell lymphoma in complete remission following allogeneic bone marrow transplantation from an HLA-matched unrelated donor. Acta Haematol 2001; 105:49-52. [PMID: 11340254 DOI: 10.1159/000046533] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Gamma/delta T cell lymphoma is very rare, and usually occurs as an extranodal tumor. We describe the case of a 16-year-old Japanese man with an unusual nodal gamma/delta T cell lymphoma with generalized lymphadenopathy and bone marrow involvement. No tumor involvement was observed in the liver, spleen, or nasal cavity. Examination for surface antigens on lymphoma cells revealed a unique phenotype, positive for CD3 and T cell receptor (TCR) gamma/delta, but negative for CD2. Genotypic analysis revealed the tumor to be of monoclonal origin and characterized by TCR gamma-chain gene rearrangement, but there was no rearrangement of the TCR beta-chain gene. Our patient's tumor responded to combination chemotherapy and subsequent allogeneic bone marrow transplantation from an HLA-matched unrelated donor. He has remained well and free of disease for 35 months.
Collapse
Affiliation(s)
- Y Aoyama
- Department of Clinical Hematology, Osaka City University Medical School, 1-4-3, Asahimachi, Abeno-ku, Osaka 545-8586, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Takeoka Y, Hino M, Oiso N, Nishi S, Koh KR, Yamane T, Ohta K, Nakamae H, Aoyama Y, Hirose A, Fujino H, Takubo T, Inoue T, Tatsumi N. Virus-associated hemophagocytic syndrome due to rubella virus and varicella-zoster virus dual infection in patient with adult idiopathic thrombocytopenic purpura. Ann Hematol 2001; 80:361-4. [PMID: 11475151 DOI: 10.1007/s002770000282] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A 26-year-old woman with idiopathic thrombocytopenic purpura (ITP) was admitted to our hospital because of fever and rash. Blood tests revealed thrombocytopenia, liver dysfunction, coagulopathy, and hyperferritinemia. Bone marrow examination revealed many atypical lymphocytes and some histiocytes with hemophagocytosis. On admission she was diagnosed with rubella virus-associated hemophagocytic syndrome (VHAS), but on laboratory examination, she was seropositive for varicella-zoster virus (VZV)-IgM as well as rubella virus-IgM. She was therefore diagnosed with dual infection by rubella virus and VZV. Her simultaneous rubella virus and VZV infection may have been related to the VAHS pathogenesis. She was treated with prednisolone and gamma globulin therapy and recovered completely.
Collapse
Affiliation(s)
- Y Takeoka
- Department of Clinical Hematology, Osaka City University Medical School, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Takubo T, Kumura T, Nakao T, Nakamae H, Aoyama Y, Nishiki S, Kinoshita Y, Koh KR, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Comparative study on complete remission rate and overall survival in three groups classified based on the serum interleukin-18 level in non-Hodgkin's lymphoma patients. Acta Haematol 2001; 104:220-2. [PMID: 11279316 DOI: 10.1159/000046520] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, 1-4-3, Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Takubo T, Tatsumi N. [Comparison of various reticulocyte counting methods and the standardization of reticulocyte counting]. Rinsho Byori 2001; 49:475-9. [PMID: 11402568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
The reticulocyte count has been conventionally determined using a visual method. Recently, due to technological advances an automated method has come into general use in laboratories. The precision in terms of reproducibility of automated reticulocyte counters has also made rapid progress compared with the visual method. The measurements of reticulocyte counts showed good correlation among the five automated reticulocyte counters and the visual method although the accuracy of an automated method is problematical since it is not sufficient to find the true value. It remains difficult to standardize reticulocyte counting because automated reticulocyte counting is performed in accordance with the procedure specified by the respective manufactures; thus, an external quality control survey was performed for an accuracy assurance of reticulocyte counts with the participation of many laboratories. In the future, it is necessary to develop biological reference materials equal to the true value or to establish other standardization using new technology.
Collapse
Affiliation(s)
- T Takubo
- Clinical Hematology and Clinical Diagnostics (Clinical and Laboratory Medicine), Graduate School of Medicine, Osaka City University, Osaka 545-8585
| | | |
Collapse
|
39
|
Takubo T, Yamane T, Hino M, Ohta K, Koh KR, Tatsumi N. Clinical significance of simultaneous measurement of reticulated platelets and large platelets in idiopathic thrombocytopenic purpura. Haematologia (Budap) 2001; 30:183-92. [PMID: 11128111 DOI: 10.1163/156855900300109189] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Frequencies of reticulated platelets (RP) and large platelets (LP) among circulating platelets can now be simultaneously determined using the R-3000 automated reticulocyte counter (Sysmex, Kobe, Japan) equipped with special software. We measured frequencies of RP and LP in patients with idiopathic thrombocytopenic purpura (ITP. acute type n = 5; chronic type n = 39), and healthy normal controls (n = 20). In ITP patients, the platelet-associated IgG (PAIgG) level was also determined. Both RP and LP were significantly higher in chronic ITP patients than those in normal volunteers, and interestingly, the LP in acute ITP was significantly lower than that in chronic ITP although there was no significant difference in RP between acute and chronic ITP. Furthermore, we analyzed the changes in both RP and LP during the clinical course of ITP to monitor the therapeutic effect in 2 patients. An elevation of RP with a steep slope prior to a decrease in the platelet count level was observed. The RP significantly correlated with the PAIgG level. Simultaneous measurement of RP and LP may be helpful for the diagnosis of chronic ITP, for the differentiation of acute from chronic type and for the control of the efficacy of management in ITP, since RP seems to reflect the disease activity of ITP.
Collapse
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Osaka, Japan.
| | | | | | | | | | | |
Collapse
|
40
|
Takubo T, Kumura T, Nakao T, Nakamae H, Aoyama Y, Nishiki S, Kinoshita Y, Koh KR, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Clinical usefulness of combined measurements of serum soluble transferrin receptor levels and serum interleukin-18 levels at determination of serum KL-6 levels in haematologic malignancies. Acta Haematol 2001; 104:141-3. [PMID: 11154993 DOI: 10.1159/000039750] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
MESH Headings
- Adult
- Antigens/blood
- Antigens, Neoplasm
- Biomarkers, Tumor/blood
- Chronic Disease
- Glycoproteins/blood
- Histiocytosis, Non-Langerhans-Cell/blood
- Hodgkin Disease/blood
- Humans
- Interleukin-18/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Myeloid, Acute/blood
- Leukemia-Lymphoma, Adult T-Cell/blood
- Lymphoma, Non-Hodgkin/blood
- Mucin-1
- Mucins
- Multiple Myeloma/blood
- Myelodysplastic Syndromes/blood
- Myeloproliferative Disorders/blood
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood
- Receptors, Transferrin/blood
- Solubility
Collapse
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Ohta K, Yamane T, Hino M, Koh KR, Nakao T, Akahori M, Kanashima H, Sakamoto E, Hagihara K, Takubo T, Tatsumi N. [Evaluation of polymerase chain reaction method for monitoring of fungal infection in compromised hosts]. Jpn J Antibiot 2001; 54:103-11. [PMID: 11392680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Diagnosis of fungal infections in compromised hosts has been difficult because of insufficient sensitivity and specificity of conventional methods such as culturing and serum testing. Therefore, antifungal agents are usually started in febrile patients who are resistant to antibiotics even if these monitoring tests were negative. In this study, therefore, in order to increase the reliability of these monitoring, polymerase chain reaction (PCR) methods for detection of blood fungus were also performed in compromised hosts including 14 patients with hematological malignancies and one with solid tumor who were undergoing chemotherapies. From these patients, total of 56 peripheral blood samples was collected periodically, irrespective of the presence of infectious signs. At each time point of venopuncture, status of the patient was allocated to one of the followings: A, receiving an intravenous antifungal therapy because of sustaining fever which had not responded to prior antibiotic therapies and also positive for culturing and/or serum beta-D-glucan tests; B, receiving an additional intravenous antifungal therapy but negative for culturing and serum-tests; C, febrile but not yet receiving any intravenous fungal therapy; D, afebrile status. During the study, 10 blood samples from 3 patients were allocated in group A, and one sample of them was positive while remaining 9 were all negative for PCR. Six samples from 4 patients were in group B, and one was PCR positive while remaining 5 were negative. Fifteen samples from 7 patients were in group C, and 3 were positive and 12 were negative for PCR. Twenty-five samples were in group D, and 5 were positive and 20 were negative for PCR. Thus, the results from fungal PCR in these patients were in some case showed discrepancies from those expected from the clinical course and/or conventional monitoring tests. Further evaluation of fungal PCR may gain insight into the more precise diagnosis of fungal infection in these patients.
Collapse
Affiliation(s)
- K Ohta
- Department of Clinical Hematology, Osaka City University Medical School
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Hasegawa T, Hino M, Yamane T, Ota K, Takubo T, Kitagawa S, Tatsumi N. [Chronic myelogenous leukemia with marked thrombocytosis]. Rinsho Ketsueki 2001; 42:199-203. [PMID: 11345782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
We report a case of chronic myelogenous leukemia (CML) with marked thrombocytosis. The patient was a 68-year-old woman who showed marked thrombocytosis (> 200 x 10(4)/microliter), a slightly increased leukocyte count without any immature myeloid cells in the peripheral blood, and no hepatosplenomegaly. Philadelphia chromosome (Ph) was detected by karyotype analysis and FISH. The bcr-abl transcript was detected by RT-PCR and the break point was located in the major bcr. Treatment with interferon-alpha was effective, reducing the proportion of Ph-positive cells from 56% to 7% within 21 months. Detailed study of atypical cases of CML such as the present one may provide additional information about the disease pathogenesis.
Collapse
Affiliation(s)
- T Hasegawa
- Department of Physiology, Osaka City University Medical School
| | | | | | | | | | | | | |
Collapse
|
43
|
Takubo T, Ohkura H, Kumura T, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Lymphoma in Castleman's disease, acute lymphocytic leukemia, adult T-cell leukemia and cutaneous T-cell lymphoma accompanied with high serum soluble Fas ligand levels. Haematologia (Budap) 2001; 30:23-6. [PMID: 10841320 DOI: 10.1163/15685590051129832] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Takubo T, Ohkura H, Kumura T, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Serum IL-18 levels in patients with various hematological disorders. Haematologia (Budap) 2001; 30:31-3. [PMID: 10841322 DOI: 10.1163/15685590051129850] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Takubo T, Tatsumi N, Tsuda I, Kasuya K, Taniguchi Y, Fujita T, Uchida K, Matsuo Y, Hayashi T. Reference values for bisphosphoglycerate mutase protein content and specific activity in human erythrocytes. Acta Haematol 2000; 99:234-5. [PMID: 9644304 DOI: 10.1159/000040846] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Takubo T, Yamane T, Hino M, Tsuda I, Tatsumi N. Usefulness of determining reticulated and large platelets in idiopathic thrombocytopenic purpura. Acta Haematol 2000; 99:109-10. [PMID: 9554462 DOI: 10.1159/000040823] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Osaka, Japan
| | | | | | | | | |
Collapse
|
47
|
Nishiki S, Yamane T, Hino M, Ohta K, Sannomiya Y, Inoue T, Takubo T, Tatsumi N. [B precursor lymphoblastic leukemia/lymphoma manifested at onset as hemophagocytic syndrome]. Rinsho Byori 2000; 48:975-9. [PMID: 11215114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
A 20 year-old male patient was admitted to our department for the treatment of recurrence of fever and pancytopenia developed despite of temporal remission of hemophagocytosis syndrome that had been treated with large doses of methylprednisolone in our hospital. Superficial lymph nodes were not palpable. CT scan and echography revealed neither findings of splenohepatomegalia or enlargement of intraabdominal lymph nodes. Bone marrow aspiration showed an increase of histiocytes, the cells phagocytizing erythrocytes and platelets, and a negative test for peroxidase stain. Analysis of surface antigens showed that 11.3% of cells were blast cells positive for CD10, CD19, CD20, CD34 and TdT. Bone marrow biopsy revealed a localized increase in tumor cells positive for L26, CD10 and negative for UCHL-1. Because of the absence of detectable tumor masses and the difficulty in differentiating between malignant lymphoma and lymphatic leukemia, we diagnosed the condition as B precursor lymphoblastic leukemia/lymphoma. If diagnosed with malignant lymphoma preceded by hemophagocytic syndrome(LAHS), he might have a rare type of LAHS-associated malignant lymphoma since histological examination did not reveal diffuse large cell lymphoma, a condition found in most patients with LAHS-associated malignant lymphoma. Whereas if diagnosed as ALL, he was the first adult patient with ALL with HPS at onset as far as we know. In any of these possibilities, the case was considered rare.
Collapse
Affiliation(s)
- S Nishiki
- Department of Clinical Hematology, Osaka City University Medical School, Osaka 545-8585
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Takubo T, Kumura T, Nishiki S, Kinoshita Y, Koh K, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Clinical significance of simultaneous determination of serum soluble transferrin receptor, soluble Fas, soluble Fas ligand, hepatocyte growth factor and interleukin 18 levels in a patient with hemophagocytic syndrome. Acta Haematol 2000; 103:165-7. [PMID: 10940656 DOI: 10.1159/000041041] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Takubo T, Okura H, Kumura T, Nishiki S, Kinoshita Y, Koh K, Ohta K, Yamane T, Hino M, Kamitani T, Tatsumi N. Human IL-18 bioactivity in hematological malignancies with highly elevated serum IL-18 levels. Acta Haematol 2000; 103:162-4. [PMID: 10940655 DOI: 10.1159/000041040] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- T Takubo
- Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Yamane T, Hino M, Ohta K, Koh KR, Nakamae H, Aoyama Y, Ota T, Kishida T, Mugitani A, Sannomiya Y, Kamitani T, Takubo T, Tatsumi N. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho 2000; 27:1547-55. [PMID: 11016000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Findings for 41 patients with non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy (HDC) and/or autologous peripheral blood stem cell transplantation (PBSCT) are reported. Two of the 41 patients were treated with HDC alone without PBSCT. At transplant, 20 patients were in complete remission, while 19 had resistant NHL and had failed to achieve a complete remission (CR) after several courses of conventional chemotherapy. The conditioning regimens used were mainly ACE (cytarabine, cyclophosphamide, etoposide) and MEAC (MCNU, etoposide, cytarabine, cyclophosphamide). The treatment-related mortality rate was 4.9%. Two patients treated with MEAC died from intractable congestive heart failure. Nine of the 19 patients with resistant NHL achieved CR, and at a median follow-up of 26 months (range, 3 to 93 months) the estimated two-year disease-free survival rate for these patients was 44.4%. Four patients in CR at present were in partial remission before HDC and PBSCT. Fifteen of the 20 patients in CR before HDC were transplanted in first CR and 5 in 2nd CR. At a median follow-up of 49 months (range, 3 to 96 months), the estimated 3-year DFS for the group of all patients was 73.7%. Five relapses occurred between 5 and 35 months post-transplantation. In conclusion, HDC and PBSCT as induction therapy was only effective for patients with resistant NHL who responded to conventional chemotherapy, and may improve the survival of patients in CR as consolidation therapy.
Collapse
Affiliation(s)
- T Yamane
- Dept. of Clinical Hematology, Osaka City University
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|